3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
15
Prostatic Neoplasms
10
Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Cardiovascular Diseases
3
Cardiotoxicity
3
Rectal Neoplasms
2
Polycystic Ovary Syndrome
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Kidney Neoplasms
2
Heart Failure
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Hyperplasia
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Venous Thrombosis
1
Urogenital Neoplasms
1
Smoking
1
Interventions
Bevacizumab
4
Temozolomide
3
Irinotecan
3
Sorafenib
2
Radiosurgery
2
pembrolizumab
1
ibrutinib
1
Vorinostat
1
Valproic Acid
1
Transcranial Magnetic Stimulation
1
Therapeutics
1
Thalidomide
1
Standard of Care
1
Sildenafil Citrate
1
Radiotherapy
1
Pliability
1
Plasma Exchange
1
Palliative Care
1
Nivolumab
1
Morphine
1
Methadone
1
Lenalidomide
1
Immunoglobulins
1
Exercise
1
Equipment and Supplies
1
Clomipramine
1
Carboplatin
1
Bendamustine Hydrochloride
1
Atorvastatin
1
Amifampridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neurologic Manifestations
×
Atorvastatin
×
Clear all
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled